In the latest episode of Exchanges at Goldman Sachs, Salveen Richter, Lead Analyst for the U.S. Biotechnology Sector in Goldman Sachs Research, explains how new innovations in gene editing are transforming the future of medicine and the greater biotech investment landscape.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Gene Editing: The Future of Genomic Medicine & Biotech Investing | Goldman Sachs Exchanges podcast - Listen or read transcript on Metacast
